Omega Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Omega Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-45,700	Closed	-$595K	–	84
2016 Q3	$595K	Sell	45,700 -4,300	-9%	-$57K	0.02%	74
2016 Q2	$696K	Buy	+50,000	New	+$736K	0.02%	74
2016 Q1	–	Sell	-118,600	Closed	-$2.25M	–	83
2015 Q4	$2.25M	Sell	118,600 -23,500	-17%	-$449K	0.05%	57
2015 Q3	$2.7M	Buy	142,100 +1,800	+1%	+$44.9K	0.05%	71
2015 Q2	$3.62M	Buy	+140,300	New	+$3.98M	0.06%	88

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Omega Advisors's PRTK Position: Q4 2016 in Review

Omega Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2016, closing a stake of 45,700 shares — an estimated $595K sold.

Omega Advisors first reported a position in PRTK in Q2 2015 and held it in 5 quarters. The position peaked at $3.62M in Q2 2015. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

Omega Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Omega Advisors sold 45,700 Paratek Pharmaceuticals, Inc. shares in Q4 2016, an estimated $595K.
Omega Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 5 quarters.
Omega Advisors's Paratek Pharmaceuticals, Inc. position peaked at $3.62M in Q2 2015.
92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on Omega Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.